Recurrent Melanoma Clinical Trial
Official title:
A Phase II Correlative Clinical Trial of MLN8237, a Selective Aurora Kinase A (AURKA) Inhibitor, in Patients With Unresectable Stage III or Stage IV Melanoma Disease
RATIONALE: Aurora A kinase inhibitor MLN8237 may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth.
PURPOSE: This phase II trial is studying how well Aurora A kinase inhibitor MLN8237 works in
treating patients with unresectable stage III-IV melanoma
Funding Source - FDA OOPD
PRIMARY OBJECTIVES:
I. Estimate the degree of clinical benefit based primarily on objective clinical responses
with AURKA inhibitor, MLN8237 in patients with metastatic melanoma in a phase II, 2-stage
trial for patients with measurable unresectable disease.
SECONDARY OBJECTIVES:
I. Assess the progression-free survival and overall survival for all patients enrolled.
II. Define toxicities due to MLN8237 and characterize their severity both over a short and
prolonged duration of administration.
III. In patients entered on stage 1 of clinical trial whenever possible through
pre-treatment biopsy and post-treatment surgical specimen, we will define target inhibition
at tumor sites based on: AURKA autophosphorylation (AURKAThr288/AURKA), intra-tumoral drug
levels, expression of p53-induced NOXA and PUMA expression, TPX2, (by IHC) and TUNEL as
markers of apoptosis, cell cycle changes (mitotic index), proliferation (Ki-67), aneuploidy,
and AKT phosphorylation.
IV. All phase II trial patients enrolled on the 2nd stage will have pre- and post-treatment
biopsies (post-day 7+/-3 days) to demonstrate that AURKA is inhibited based on
autophosphorylation AURKA/AURKA^Thr 288, Histone H3 (at S10) phosphorylation, AKT
phosphorylation, cell cycle changes (mitotic index), TPX2 (by IHC), proliferation (Ki-67),
aneuploidy, and p53-induced NOXA and PUMA expression, and TUNEL as markers of apoptosis.
V. Demonstrate any correlation between MLN8237 induced target inhibition at tumor sites and
clinical benefit of MLN8237.
VI. Characterize the de novo molecular mutational profile of the melanomas from all patients
entered using a developed SNaPshot assay for melanoma in addition loss of regulatory
proteins (i.e., PTEN), DNA copy numbers and gene expression (AURKA), and autophosphorylation
of AURKA as well as AURKA localization by IHC.
OUTLINE: Patients receive oral Aurora A kinase inhibitor MLN8237 every 12 hours on days 1-7.
Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 1 year and
then every 6 months for 5 years.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02224781 -
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
|
Phase 3 | |
Completed |
NCT01886235 -
Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery
|
N/A | |
Completed |
NCT00553306 -
Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma
|
Phase 1/Phase 2 | |
Completed |
NCT00121225 -
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
|
Phase 2 | |
Completed |
NCT00019448 -
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT01961115 -
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
|
Phase 2 | |
Completed |
NCT01748747 -
Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery
|
Early Phase 1 | |
Active, not recruiting |
NCT01120275 -
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma
|
Phase 2 | |
Terminated |
NCT01217411 -
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
|
Phase 1 | |
Terminated |
NCT01166126 -
Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
|
Phase 2 | |
Completed |
NCT01037790 -
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
|
Phase 2 | |
Completed |
NCT00288041 -
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT00072163 -
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
|
Phase 2 | |
Completed |
NCT00074308 -
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
|
Phase 1/Phase 2 | |
Completed |
NCT01989559 -
Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery
|
Phase 1 | |
Completed |
NCT00026143 -
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
|
Phase 2 | |
Completed |
NCT00006243 -
Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma
|
N/A | |
Active, not recruiting |
NCT04284774 -
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
|
Phase 2 | |
Completed |
NCT01703507 -
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma
|
Phase 1 | |
Withdrawn |
NCT03220009 -
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
|
Phase 2 |